Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved doxorubicin in combination with cyclophosphamide (AC 60/600) 21 day followed by weekly paclitaxel (80) and weekly trastuzumab therapy (ac-th) for reimbursement as a treatment option for the neoadjuvant treatment of HER2 positive, high risk node negative or node positive breast cancer.
This is written in the approval document as:
Neoadjuvant Treatment of HER2 positive, High Risk Node Negative or Node Positive Breast Cancer.
Citation
DOXOrubicin, cycloPHOSphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH), 2023, version number 4, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/432-doxorubicin-cyclophosphamide-followed-by-weekly-paclitaxel-80-and-weekly-trastuzumab-therapy-ac-th-.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | HER2-positive | Invasive Breast Carcinoma | Cyclophosphamide, Doxorubicin, Paclitaxel, Trastuzumab |